The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 21, 2021

Filed:

Dec. 07, 2020
Applicant:

Vicore Pharma Ab, Stockholm, SE;

Inventors:

Carl-Johan Dalsgaard, Stockholm, SE;

Johan Raud, Stockholm, SE;

Rohit Batta, Stockholm, SE;

Assignee:

VICORE PHARMA AB, Stockholm, SE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4178 (2006.01); A61P 31/14 (2006.01); A61K 31/16 (2006.01); A61K 31/573 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); A61K 31/513 (2006.01); A61K 31/7056 (2006.01); A61K 31/706 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4178 (2013.01); A61K 31/16 (2013.01); A61K 31/513 (2013.01); A61K 31/573 (2013.01); A61K 31/706 (2013.01); A61K 31/7056 (2013.01); A61K 38/215 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01);
Abstract

There is provided N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide, or a pharmaceutically-acceptable salt thereof, for use in a method of treatment of respiratory virus-induced tissue damage. Such damage may be caused by coronaviruses, including severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus. N-Butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide alleviate symptoms of diseases caused by those viruses (including coronavirus disease 2019 or COVID-19), such as cough, dyspnea, pneumonia, respiratory distress, respiratory failure and/or fibrosis of organs such as the lungs, the heart or the kidneys, and may thus prevent respiratory virus-induced morbidity and/or mortality. In particular, it has been found in a clinical study that the proportion of patients with COVID-19 needing oxygen treatment was significantly lower for patients that were administered N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-iso-butylthiophene-2-sulfonamide compared to placebo.


Find Patent Forward Citations

Loading…